ST-11: a new brain-penetrant microtubule-destabilizing agent with therapeutic potential for glioblastoma multiforme
AE Cherry, BR Haas, AV Naydenov, S Fung, C Xu… - Molecular cancer …, 2016 - AACR
Glioblastoma multiforme is a devastating and intractable type of cancer. Current
antineoplastic drugs do not improve the median survival of patients diagnosed with
glioblastoma multiforme beyond 14 to 15 months, in part because the blood–brain barrier is
generally impermeable to many therapeutic agents. Drugs that target microtubules (MT)
have shown remarkable efficacy in a variety of cancers, yet their use as glioblastoma
multiforme treatments has also been hindered by the scarcity of brain-penetrant MT …
antineoplastic drugs do not improve the median survival of patients diagnosed with
glioblastoma multiforme beyond 14 to 15 months, in part because the blood–brain barrier is
generally impermeable to many therapeutic agents. Drugs that target microtubules (MT)
have shown remarkable efficacy in a variety of cancers, yet their use as glioblastoma
multiforme treatments has also been hindered by the scarcity of brain-penetrant MT …
[PDF][PDF] ST-11: a new brain-penetrant microtubule-destabilizing agent with therapeutic potential
LW Liggitt, N Stella - faculty.washington.edu
Glioblastoma multiforme (GBM) is a devastating and intractable type of cancer. Current
antineoplastic drugs do not improve the median survival of patients diagnosed with GBM
beyond 14-15 months in part because the blood-brain barrier is generally impermeable to
many therapeutic agents. Drugs that target microtubules (MT) have shown remarkable
efficacy in a variety of cancers, yet their use as GBM treatments has also been hindered by
the scarcity of brain-penetrant MT-targeting compounds. We have discovered a new …
antineoplastic drugs do not improve the median survival of patients diagnosed with GBM
beyond 14-15 months in part because the blood-brain barrier is generally impermeable to
many therapeutic agents. Drugs that target microtubules (MT) have shown remarkable
efficacy in a variety of cancers, yet their use as GBM treatments has also been hindered by
the scarcity of brain-penetrant MT-targeting compounds. We have discovered a new …
以上显示的是最相近的搜索结果。 查看全部搜索结果